Quick Answer
Valion Bio, Inc. reported Operating Income of -$7.90 million for fiscal year 2025.
Valion Bio, Inc. Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$7.90M | -76.5% |
| 2024 | -$4.48M | +45.7% |
| 2023 | -$8.24M | +18.4% |
| 2022 | -$10.10M | -79.3% |
| 2021 | -$5.63M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$2.48M | -73.5% | -28.4% |
| June 30, 2025 | -$1.93M | -52.8% | -28.4% |
| March 31, 2025 | -$1.51M | -1.7% | -5.2% |
| September 30, 2024 | -$1.43M | +18.7% | -13.0% |
| June 30, 2024 | -$1.27M | +40.4% | +14.5% |
| March 31, 2024 | -$1.48M | +30.0% | +15.9% |
| September 30, 2023 | -$1.76M | +31.9% | +17.2% |
| June 30, 2023 | -$2.12M | +29.6% | -0.4% |
- Valion Bio, Inc. showed a decrease of -76.5% in Operating Income compared to the prior fiscal year.
- Over the 2021–2025 period, Valion Bio, Inc.’s operating income has declined by 40.2% (from -$5.63 million to -$7.90 million).
- The most recent figure is from Valion Bio, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: